The EASL guidelines on the clinical management of hereditary cholestatic liver disease, published in 2024, suggest that genetic testing should be performed as early as possible in the diagnostic process after ruling out common causes. Along with a better understanding of the genes and proteins involved in biliary homeostasis and the increasing availability of genetic testing, more and more patients with adult-onset cholestasis are being tested for cholestasis genes that play a role in progressive intrahepatic familial cholestasis (PFIC).
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Acute leukemia: Disease management
Priorities from the perspective of patients and family caregivers
- Bronchodilators for asthma
The early bird … gasps for air
- Chronic kidney disease (CKD)
Triage of high-risk patients – Update 2025
- AAD Annual Meeting: Review
HS and acne – what’s new?
- New perspectives for the optimization of cancer immunotherapy
Nanoparticle-mediated intratumoral gene editing of PD-L1 and galectin-9
- Past, present and future
Biomarkers in schizophrenia
- From genome profiles to targeted therapies
Advances in breast cancer therapy in the age of molecular diagnostics
- Current overview of evidence, mechanisms and clinical implications